CeriBell (CBLL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.40
- Estimate
- -$0.46
- Surprise
- +11.9%
- Revenue (period 2026-06-30)
- $28.1M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
CeriBell (CBLL) reported a narrower loss than forecast — diluted EPS of -$0.40 against the -$0.46 estimate (a 11.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CBLL Sell at 5.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +11.9% surprise compares with a +9.7% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Product: Ceribell System
- Concentration risk — Geographic: United States sales (100.0%)
- Target reached (-0.6% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $24.50
- Price target
- $25.12
- Stop
- $22.79
- Upside to target
- +2.5%
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
CBLL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $961.0M
- P/E (fwd)
- -15.5
- 52-week range
- $10.85–$25.33
- Off 52-week high
- 3.3%
- RSI (14)
- 59
- Volume vs avg
- 1.46×
- Score today
- 5.6/10